WST has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
WST has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-25), West Pharmaceutical Services's share price is $231.90. West Pharmaceutical Services's Book Value per Share for the quarter that ended in Dec. 2024 was $37.10. Hence, West Pharmaceutical Services's PB Ratio of today is 6.25.
Good Sign:
West Pharmaceutical Services Inc stock PB Ratio (=6.25) is close to 5-year low of 5.68
The historical rank and industry rank for West Pharmaceutical Services's PB Ratio or its related term are showing as below:
During the past 13 years, West Pharmaceutical Services's highest PB Ratio was 16.91. The lowest was 3.86. And the median was 7.31.
During the past 12 months, West Pharmaceutical Services's average Book Value Per Share Growth Rate was -5.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 5.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 13.00% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 12.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of West Pharmaceutical Services was 19.50% per year. The lowest was -7.00% per year. And the median was 9.30% per year.
The historical data trend for West Pharmaceutical Services's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
West Pharmaceutical Services Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
PB Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
11.30 | 14.90 | 6.50 | 8.98 | 8.83 |
West Pharmaceutical Services Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
PB Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
8.98 | 10.78 | 9.28 | 7.91 | 8.83 |
For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's PB Ratio distribution charts can be found below:
* The bar in red indicates where West Pharmaceutical Services's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
West Pharmaceutical Services's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Dec. 2024) |
= | 231.90 | / | 37.1 | |
= | 6.25 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
West Pharmaceutical Services (NYSE:WST) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of West Pharmaceutical Services's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles Witherspoon | officer: VP & Treasurer | 530 HERMAN O WEST DRIVE, EXTON PA 19341 |
Eric Mark Green | officer: Chief Executive Officer | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
Silji Abraham | officer: Chief Digital & Trans Officer | 5000 TOWN CENTER, U, SOUTHFIELD MI 48075 |
Thomas W Hofmann | director | FIVE RADNOR CORPORATE CENTER, SUITE 500, RADNOR PA 19087 |
Chad Winters | officer: VP, CAO & Controller | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
Annette F Favorite | officer: Sr. VP Human Resources Officer | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
Cindy Reiss-clark | officer: Senior Vice President | 530 HERMAN O. WEST DRIVE, EXTON PA 19341-1147 |
Quintin J Lai | officer: VP Corp Development & Strategy | 530 HERMAN 0. WEST DRIVE, EXTON PA 19341 |
Bernard Birkett | officer: Sr VP, CFO & Treasurer | 1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095 |
Stephen H Lockhart | director | C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508 |
Molly Joseph | director | 9209 GRAND SUMMIT BLVD, DRIPPING SPRINGS TX 78620 |
Kimberly Banks Mackay | officer: SVP, GC & Corporate Secretary | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
George Lloyd Miller | officer: Sr. VP, GC & Corp. Sec. | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
David A Montecalvo | officer: SVP, Glob Ops and Supply Chain | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
Robert F Friel | director | 940 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By GuruFocus News • 01-22-2025
By PRNewswire • 02-20-2025
By PRNewswire • 01-06-2025
By GuruFocus News • 02-14-2025
By GuruFocus News • 03-05-2025
By GuruFocus News • 03-03-2025
By GuruFocus News • 02-14-2025
By GuruFocus News • 11-15-2024
By GuruFocus News • 01-28-2025
By GuruFocus News • 12-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.